Trial · NCT02446899
Trial comparisons11
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 11 of 11
Download this page as JSON| Comparison | Source |
|---|---|
| Anifrolumab 300 mg vs Placebo: Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline | Trial comparisons |
Anifrolumab 300 mg vs Placebo: Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants With One or More Adverse Events (AEs) | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants With One or More Adverse Events of Special Interest (AESIs) | Trial comparisons |
Anifrolumab 300 mg vs Placebo: Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: deaths from any cause | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02446899/comparisons